M04NM11

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameM04NM11

Drug Alias NameHepatitis B Virus immunobioticM04NM11 hepatitis B immunotherapyLive attenuated Salmonella enterica serovar Typhi (Ty2 aroCssaV- ssaG-HBcAg) RSC5Hepatitis B Candidate 1

ClassificationVaccines > Development/production technology > Live attenuated vaccineVaccines > Application > Therapeutic vaccine

Mechanisms of ActionImmunostimulantsGene transference

TargetsNot applicable

Therapy Area/IndicationsHepatitis B

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesEmergent Biosolutions Inc

China Registration ClassN/A

Develop Information

Active CompaniesEmergent Biosolutions Inc

Inactive CompaniesN/A

Active IndicationsHepatitis B

Inactive IndicationsN/A

Other Information

ATC CodeN/A